Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2021.6846
Abstract: Importance Matched sibling donors (MSDs) are preferred for allogeneic hematopoietic cell transplantation (allo-HCT) in myelodysplastic syndrome even if they are older. However, whether older MSDs or younger human leukocyte antigen-matched unrelated donors (MUDs) are associated… read more here.
Keywords: survival; free survival; allo hct; older msds ... See more keywords
Nonhealing Cutaneous Ulcers in a Patient With Myelodysplastic Syndrome.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2023.0193
Abstract: A 75-year-old man with myelodysplastic syndrome that has been well controlled with lenalidomide develops multiple nonhealing cutaneous ulcers. What is your diagnosis? read more here.
Keywords: cutaneous ulcers; ulcers patient; nonhealing cutaneous; patient myelodysplastic ... See more keywords
A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study)
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Hematology"
DOI: 10.1002/ajh.24905
Abstract: Hypoplastic myelodysplastic syndrome (hMDS) is a distinct entity with bone marrow (BM) hypocellularity and the risk of death from BM failure (BMF). To elucidate the characteristics of hMDS, the data of 129 patients diagnosed between… read more here.
Keywords: risk; hmds; myelodysplastic syndrome; hypoplastic myelodysplastic ... See more keywords
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T) and myelodysplastic syndrome with ring sideroblasts (MDS‐RS)
Sign Up to like & getrecommendations! Published in 2021 at "American Journal of Hematology"
DOI: 10.1002/ajh.26182
Abstract: REFERENCES 1. Kumar SK, Callander NS, Hillengass J, et al. NCCN guidelines insights: multiple myeloma, version 1.2020. J Natl Compr Canc Netw. 2019;17 (10):1154-1165. 2. Cheson BD, Leoni L. Bendamustine: mechanism of action and clinical… read more here.
Keywords: genomic transcriptomic; ring sideroblasts; multiple myeloma; myelodysplastic syndrome ... See more keywords
Effect of mutation allele frequency on the risk stratification of myelodysplastic syndrome patients
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26734
Abstract: Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal myeloid malignancies. Though several recurrent mutations are closely correlated with clinical outcomes, data concerning the association between mutation variant allele frequencies (VAF) and prognosis are limited.… read more here.
Keywords: risk stratification; risk; allele; mutation ... See more keywords
Health‐related quality of life in reduced‐intensity hematopoietic cell transplantation based on donor availability in patients aged 50–75 with advanced myelodysplastic syndrome: BMT CTN 1102
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26768
Abstract: For myelodysplastic syndrome (MDS), allogeneic hematopoietic cell transplantation (alloHCT) is the only available curative therapy. The Blood and Marrow Transplant Clinical Trials Network study 1102 (BMT CTN 1102, NCT02016781) was a multicenter, biologic assignment trial… read more here.
Keywords: donor availability; bmt ctn; cell transplantation; availability ... See more keywords
Pre‐transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Communications"
DOI: 10.1002/cac2.12140
Abstract: The role of pre‐hematopoietic stem cell transplantation (HSCT) cytoreduction with either induction chemotherapy (IC) or hypomethylating agents (HMAs) in treating advanced myelodysplastic syndrome (MDS) remains debatable. We aimed to evaluate pre‐HSCT strategies by comparing the… read more here.
Keywords: advanced myelodysplastic; pre transplantation; myelodysplastic syndrome; transplantation ... See more keywords
Fatigue, symptom burden, and health‐related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.1953
Abstract: Fatigue is distressing and affects quality of life (QoL) among patients with myelodysplastic syndrome (MDS), aplastic anemia (AA), and paroxysmal nocturnal hemoglobinuria (PNH). Limited data exist on the impact of fatigue, QoL, and related symptoms… read more here.
Keywords: aplastic anemia; patients myelodysplastic; fatigue; anemia paroxysmal ... See more keywords
Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population‐based study among older breast cancer patients
Sign Up to like & getrecommendations! Published in 2018 at "Cancer"
DOI: 10.1002/cncr.31144
Abstract: Chemotherapy for early breast cancer is associated with a small risk of developing myelodysplastic syndrome (MDS) and/or acute myeloid leukemia (AML). The aim of this study was to determine the risk of developing AML or… read more here.
Keywords: chemotherapy; breast cancer; myelodysplastic syndrome; acute myeloid ... See more keywords
Five‐day versus 7‐day treatment regimen with azacitidine in lower risk myelodysplastic syndrome: A phase 2, multicenter, randomized trial
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34492
Abstract: Low‐dose azacitidine (AZA) regimens, primarily 5‐day AZA, have been used in lower risk myelodysplastic syndrome (LrMDS) but they have yet to be directly compared to the standard 7‐day, uninterrupted dosing schedule. read more here.
Keywords: day; five day; risk myelodysplastic; myelodysplastic syndrome ... See more keywords
TP53‐altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34535
Abstract: TP53‐altered myelodysplastic syndrome with excess blasts and TP53‐altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for… read more here.
Keywords: tp53 altered; altered acute; excess blasts; acute myeloid ... See more keywords